Dexmedetomidine Versus Propofol in Vitreoretinal Surgery
Recruiting in Palo Alto (17 mi)
+1 other location
AP
Overseen byAnuradha Patel, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 4
Waitlist Available
Sponsor: Rutgers, The State University of New Jersey
No Placebo Group
Prior Safety Data
Trial Summary
What is the purpose of this trial?
The investigators would like to determine if using Dexmedetomidine alone or in a reduced dose can prevent or reduce the incidence of adverse effects, while providing adequate sedation, and respiratory stability as compared to propofol.
Research Team
AP
Anuradha Patel, MD
Principal Investigator
Rutgers /NJMS
Eligibility Criteria
Inclusion Criteria
American Society of Anesthesiologists rating of I-III
good renal and liver function
Treatment Details
Interventions
- Dexmedetomidine (Alpha-2 Agonist)
- Propofol (General Anesthetic)
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: dexmedetomidine infusionExperimental Treatment1 Intervention
Subject will receive a bolus of0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug.
Group II: PropofolActive Control1 Intervention
propofol 1mg/kg as a bolus intravenously followed by an infusion of 25-100 ug/kg/min
Dexmedetomidine is already approved in Canada, Japan for the following indications:
Approved in Canada as Precedex for:
- Sedation in intensive care settings
- Procedural sedation
Approved in Japan as Precedex for:
- Sedation in intensive care settings
- Procedural sedation
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
UMDNJ-University HospitalNewark, NJ
University HospitalNewark, NJ
Loading ...
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor
Trials
471
Patients Recruited
81,700+